AOD-9604 is a synthetic peptide fragment derived from human growth hormone, designed to stimulate fat metabolism without producing the broader hormonal effects of full growth hormone. It works through a specific receptor pathway that signals fat cells to release stored fat for energy — without affecting blood sugar, IGF-1, or appetite.

This guide covers what AOD-9604 actually is (and isn’t), how it works at the receptor level, what the clinical research shows, who developed it, its FDA status, realistic expectations, and how it compares to other weight loss peptides like semaglutide and tirzepatide.

Quick Answer: AOD-9604 at a Glance

What is AOD-9604?

AOD-9604 — short for Anti-Obesity Drug 9604 — is a modified peptide fragment consisting of the terminal 15 amino acids of human growth hormone (positions 176–191) with a tyrosine residue added at the N-terminus to improve stability.

It’s sometimes called the “lipolytic fragment” of growth hormone because it isolates one specific function — fat metabolism — while bypassing the pathways responsible for growth, blood sugar effects, and tissue proliferation. This selectivity is what makes AOD-9604 different from full growth hormone (GH) therapy, which carries broader hormonal effects.

How Does AOD-9604 Work?

AOD-9604 works through a fundamentally different mechanism than appetite-suppressing peptides like semaglutide or tirzepatide. Instead of reducing hunger, it directly signals fat cells to release stored fat for energy.

Research indicates AOD-9604 acts primarily through the beta-3 adrenergic receptor pathway in adipose tissue. Activation of this pathway produces two key effects:

1. Stimulates lipolysis — the breakdown of stored triglycerides into free fatty acids that the body can use as fuel
2. Inhibits lipogenesis — the formation and storage of new fat tissue

Critically, AOD-9604 produces these fat-mobilizing effects without activating the IGF-1 axis or affecting glucose metabolism — distinguishing it sharply from full growth hormone.

What AOD-9604 Doesn’t Do

This is where AOD-9604 differs most from full growth hormone, and where most marketing copy gets it wrong. Clinical research has consistently shown that AOD-9604:

• Does not elevate IGF-1 levels — so it doesn’t drive the tissue growth effects associated with GH
• Does not impair insulin sensitivity — an important distinction from full GH, which can cause insulin resistance
• Does not affect blood glucose — safe for those without underlying glucose abnormalities (always confirm with your physician)
• Does not produce stimulant effects — no jitters, elevated heart rate, or sleep disruption like with thermogenics
• Does not suppress appetite — it works through fat cells, not hunger pathways

This selectivity is why AOD-9604 is commonly stacked with GLP-1 peptides — the mechanisms don’t overlap. GLP-1s reduce hunger; AOD-9604 mobilizes fat. Together, they cover both sides of the energy-balance equation.

Who Developed AOD-9604?

AOD-9604 was developed by Metabolic Pharmaceuticals, an Australian biotech company, in the late 1990s through the mid-2000s. The peptide was studied extensively across six randomized, double-blind, placebo-controlled clinical trials involving over 900 participants. These studies established AOD-9604’s safety profile and the dosing parameters that physicians still reference today.

Is AOD-9604 FDA Approved?

No — AOD-9604 is not FDA-approved as a standalone weight loss medication. The Phase IIb trial that ran in the early 2000s did not produce statistically significant weight loss compared to placebo at the 12-week primary endpoint, and Metabolic Pharmaceuticals discontinued the drug development pathway in 2007.

However, AOD-9604 is compounded by licensed pharmacies for use under physician supervision as part of broader metabolic health protocols. This is the same regulatory framework that applies to many compounded medications used in personalized medicine.

What this means practically:

• AOD-9604 is legal to prescribe and dispense through licensed U.S. compounding pharmacies
• It requires physician supervision and a valid prescription
• It is not marketed as an FDA-approved weight loss drug
• It is used off-label for fat metabolism support alongside lifestyle modification

At Wittmer Rejuvenation Clinic, AOD-9604 troches are dispensed through our partnered licensed compounding pharmacy after physician review.

Realistic Expectations From AOD-9604

This is where most peptide content oversells. We won’t.

The clinical trial data show that AOD-9604, used in isolation, produces modest fat-loss effects. In the published 12-week studies, average fat reduction was approximately 2.6 kg (about 5.7 pounds) compared to 0.8 kg in placebo groups — meaningful, but not dramatic. The larger Phase IIb trial didn’t reach statistical significance for weight loss as a standalone intervention.

What this tells us: AOD-9604 is not a magic bullet. It works best as one component of a broader fat-loss protocol that includes:

• A structured nutrition plan with adequate protein (0.8–1.2 g per pound of bodyweight)
• Resistance training to preserve lean mass during fat loss
• Adequate sleep (when growth hormone naturally peaks)
• Stress and cortisol management

Many WRC patients use AOD-9604 alongside semaglutide or tirzepatide to combine appetite control (GLP-1 mechanism) with direct fat mobilization (AOD-9604 mechanism) for compounding effects. See our Top Peptides for Weight Loss guide for stacking considerations.

Benefits of AOD-9604

Targeted Fat Metabolism

AOD-9604’s primary benefit is supporting the body’s natural fat-breakdown processes. It helps release stored fat for energy while reducing the formation of new fat cells — without affecting other metabolic pathways.

Metabolically Selective

Unlike full GH or stimulant-based fat burners, AOD-9604 doesn’t affect blood sugar, IGF-1, blood pressure, or heart rate. This makes it an option for people who can’t tolerate stimulants or who want fat-loss support without broader hormonal effects.

Convenient Oral Delivery

WRC dispenses AOD-9604 as a dissolvable troche rather than an injection. For patients who prefer to avoid needles, this is a meaningful practical advantage.

Compatible With Other Therapies

Because AOD-9604 works through a different mechanism than GLP-1 peptides or hormone replacement, it can typically be combined with other treatments under physician supervision.

Who May Benefit From AOD-9604?

AOD-9604 may be appropriate for:

• Those struggling with stubborn fat that hasn’t responded to diet and exercise alone
• Individuals looking for metabolic support without stimulant or appetite-suppressant effects
• People who want fat-loss support without the broader effects of growth hormone
• Those combining peptide therapy with a structured nutrition and training program
• Patients already on a GLP-1 (semaglutide/tirzepatide) who want to add a complementary mechanism
• Those who prefer oral troches over injections

How to Take AOD-9604

AOD-9604 at WRC is dispensed as oral dissolvable troches. The standard protocol is one 300mcg troche daily, dissolved under the tongue or between the cheek and gum, taken on an empty stomach in the morning. A typical course runs 12 weeks followed by a 4-week break, with adjustments based on individual response.

For full dosing instructions, see the AOD-9604 Treatment Plan, and use our peptide dosage calculator if you need to verify dosing math.

AOD-9604 vs Other Weight Loss Peptides

AOD-9604 takes a fundamentally different approach than the GLP-1 receptor agonists that dominate weight loss conversations:

• vs. Semaglutide / Tirzepatide: GLP-1s suppress appetite and slow gastric emptying. AOD-9604 directly mobilizes fat from cells. Different mechanisms, often stacked together.
• vs. Tesamorelin: Tesamorelin works upstream by stimulating natural GH release. AOD-9604 acts directly on fat cells without affecting GH levels.
• vs. 5-Amino-1MQ: 5-Amino-1MQ inhibits the NNMT enzyme to shift metabolism. AOD-9604 acts at the receptor level. Both can complement each other.

For a full comparison, see Top Peptides for Weight Loss.

About This Guide

This article was prepared by the clinical team at Wittmer Rejuvenation Clinic and reviewed by Dr. Michael Wittmer, ABHRT-certified, our Clinical Director. WRC is a nationwide telemedicine clinic serving patients in all 50 states with physician-supervised peptide therapy and hormone optimization. Our practice currently holds 836 Google reviews with an average 4.9-star rating.

For specific dosing protocols or to discuss whether AOD-9604 is appropriate for your goals, our clinical team is available via text during business hours.

Frequently Asked Questions About AOD-9604